Gradalis
The firm is refining a biomarker strategy, with which it hopes to identify ovarian cancer patients who will respond best to the therapy, dubbed Vigil.
The firm is refining a biomarker strategy, with which it hopes to identify ovarian cancer patients who will respond best to the therapy, dubbed Vigil.